|Bid||10.36 x 1400|
|Ask||10.40 x 1400|
|Day's Range||10.21 - 10.59|
|52 Week Range||2.12 - 33.79|
|Beta (5Y Monthly)||1.02|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) for breaches of fiduciary duties and violations of the Securities Exchange Act of 1934. Inovio is a late-stage biotechnology Company that focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines.
NEW YORK, NY / ACCESSWIRE / May 12, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased ...
Los Angeles, California--(Newsfile Corp. - May 12, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Inovio Pharmaceuticals, Inc. (NASDAQ: INO) ("Inovio" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 14, 2020 and March 9, 2020, inclusive ...